A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)
Recruiting · Phase 2 · NCT06794541
Conditions: Complicated Intra-abdominal Infections (cIAI)
At a glance
- Research payments reported, 2025
- $231,378
- U.S. investigators named
- 5
- Sites paid
- 5
- Planned or actual enrollment
- 35
About the trial
- Sponsor
- Tetraphase Pharmaceuticals, Inc (with Innoviva Specialty Therapeutics)
- Tested
- IV Eravacycline 2mg/kg (drug), IV Eravacycline 1.5mg/kg (drug)
- Dates
- Started 2025-05-22; completion 2029-03-19
- Results posted
- Not yet
A Phase 2 trial to assess safety, tolerability, and pharmacokinetics of eravacycline in pediatric patients aged 8 to \<18 years with cIAI.
From ClinicalTrials.gov, last updated 2026-05-05. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Tetraphase Pharmaceuticals, Inc. reported $231,378 in research payments for this study in 2025 (25 payments).
Products named: Xerava
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jaime G. Deville, M.D. Pediatric Infectious Disease · Los Angeles, CA
- Delma J. Nieves, M.D. Pediatrics · Orange, CA
- Seth D. Goldstein, M.D. Pediatric Surgery · Chicago, IL
- John A. Vanchiere, MD/PHD Pediatric Infectious Disease · Shreveport, LA
- Federico G. Seifarth, M.D., FMH,FAAP, FACS Pediatric Surgery · Morgantown, WV
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ann & Robert H Lurie Childrens Hospital of Chicago, IL $72,533
- West Virginia University $57,893
- Children's Hospital of Orange County, CA $41,698
- Ronald Reagan UCLA Medical Center, CA $36,787
- Lsu Health Sciences Center $22,467
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.